psma-targeted [in-111]-labeled trillium compound
PeptideexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 8, 2022 (NCT05773703)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 111-indium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06217822 | Phase 1 | Mar 7, 2024 | Bayer |
| NCT05773703 | Early Phase 1 (Phase 1) | Dec 8, 2022 | Ratio Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 1 | 1 | 1 | 2024 |
| Ratio Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1